Interstitial lung disease and anti-Jo-1 antibodies: Difference between acute and gradual onset

Thorax

Volumn 63, Issue 1, 2008, Pages 53-59

  Tillie Leblond, I ^a,h   Wislez, M ^a   Valeyre, D ^b   Crestani, B ^c   Rabbat, A ^d   Israel Biet, D ^e   Humbert, M ^f   Couderc, L J ^g   Wallaert, B ^h   Cadranel, J ^a  

^a HÔPITAL TENON   (France)

^b AVICENNE HOSPITAL   (France)

^c BICHAT HOSPITAL   (France)

^d HÔTEL DIEU   (France)

^e HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^f HÔPITAL ANTOINE BÉCLÈRE   (France)

^g FOCH HOSPITAL   (France)

^h LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; AZATHIOPRINE; CORTICOSTEROID; CREATINE KINASE; CYCLOPHOSPHAMIDE; IMMUNOSUPPRESSIVE AGENT; JO 1 ANTIBODY; LA ANTIBODY; METHOTREXATE; RHEUMATOID FACTOR; RO ANTIBODY; SYNTHETASE; ANTINUCLEAR ANTIBODY; JO-1 ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE COURSE; DRUG FATALITY; ENZYME ASSAY; FEMALE; FEVER; FOLLOW UP; HERPES ZOSTER; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HOSPITAL ADMISSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOASSAY; INTERSTITIAL LUNG DISEASE; LUNG LAVAGE; MALE; MULTIPLE ORGAN FAILURE; MYOSITIS; NEUTROPHIL; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PREVALENCE; PRIORITY JOURNAL; RADIOLOGY; RESPIRATORY FAILURE; RETROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE; ACUTE DISEASE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CYTOLOGY; IMMUNOLOGY; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY;

ACUTE DISEASE; ADRENAL CORTEX HORMONES; ADULT; AGED; ANTIBODIES, ANTINUCLEAR; BRONCHOALVEOLAR LAVAGE FLUID; FEMALE; HUMANS; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED;

EID: 38349182194     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: 10.1136/thx.2006.069237     Document Type: Article

References (54)

1. Cottin V, Thivolet-Bejui F, Reynaud-Gaubert M, et al. Interstitial lung disease in amyopathic dermatomyositis, dermatomyositis and polymyositis. Eur Respir J 2003;22:245-50.
2. Douglas WW, Tazelaar HD, Hartman TE, et al. Polymyositis-dermatomyositis-associated interstitial lung disease. Am J Respir Crit Care Med 2001;164:1182-5.
3. Fathi M, Dastmalchi M, Rasmussen E, et al. Interstitial lung disease, a common manifestation of newly diagnosed polymyositis and dermatomyositis. Ann Rheum Dis 2004;63:297-301.
4. Grau JM, Miro O, Pedrol E, et al. Interstitial lung disease related to dermatomyositis. Comparative study with patients without lung involvement. J Rheumatol 1996;23:1921-6.
5. Kurasawa K, Nawata Y, Takabayashi K, et al. Activation of pulmonary T cells in corticosteroid-resistant and -sensitive interstitial pneumonitis in dermatomyositis/polymyositis. Clin Exp Immunol 2002;129:541-8.
6. Marie I, Hachulla E, Cherin P, et al. Interstitial lung disease in polymyositis and dermatomyositis. Arthritis Rheum 2002;47:614-22.
7. Schnabel A, Reuter M, Biederer J, et al. Interstitial lung disease in polymyositis and dermatomyositis: clinical course and response to treatment. Semin Arthritis Rheum 2003;32:273-84.
8. Schwartz MI. The lung in polymyositis. Clin Chest Med 1998;19:701-12.
9. Schwartz MI, Matthay RA, Sahn SA, et al. Interstitial lung disease in polymyositis and dermatomyositis: analysis of six cases and review of the literature. Medicine 1976;55:89-104.
10. Tazelaar HD, Viggiano RW, Pickersgill J, et al. Interstitial lung disease in polymyositis and dermatomyositis. Am Rev Respir Dis 1990;141:727-33.
11. Arsura EL, Greenberg AS. Adverse impact of interstitial pulmonary fibrosis on prognosis in polymyositis and dermatopolymyositis. Semin Arthritis Rheum 1988;18:29-37.
12. Dalakas MC. Polymyositis and dermatomyositis. Lancet 2003;362:971-82.
13. Marie I, Hachulla E, Hatron PY. Polymyositis and dermatomyositis: short term and longterm outcome, and predictive factors of prognosis. J Rheumatol 2001;28:2230-7.
14. Spath M, Schroder M, Schlotter-Weigel B, et al. The long-term outcome of anti-Jo-1-positive inflammatory myopathies. J Neurol 2004;251:859-64.
15. Sultan SM, Ioannou Y, Moss K, et al. Outcome in patients with idiopathic inflammatory myositis: morbidity and mortality. Rheumatology 2002;41:22-6.
16. Arnett FC, Hirsch TJ, Bias WB, et al. The Jo-1 antibody system in myositis: relationships to clinical features and HLA. J Rheumatol 1981;8:925-30.
17. Bernstein RM, Morgan SH, Chapman J, et al. Anti-Jo-1 antibody: a marker for myositis with interstitial lung disease. BMJ (Clin Res Ed) 1984;289:151-2.
18. Hochberg MC, Feldman D, Stevens MB, et al. Antibody to Jo-1 in polymyositis/dermatomyositis: association with interstitial pulmonary disease. J Rheumatol 1984;11:663-5.
19. Love LA, Leff R, Fraser DD, et al. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore) 1991;70:360-74.
20. Schmidt WA, Wetzel W, Friedlander R, et al. Clinical and serological aspects of patients with anti-Jo-1 antibodies: an evolving spectrum of disease manifestations. Clin Rheumatol 2000;19:371-7.
21. Yamakage A, Ishikawa H, Saito Y, et al. Occupational Scleroderma-like disorder occurring in men engaged in the polymerization of epoxy resins. Dermatologica 1980;161:33-44.
22. Friedman AW, Targoff IN, Arnett FC. Interstitial lung disease with autoantibodies against aminoacyl-tRNA synthetases in the absence of clinically apparent myositis. Semin Arthritis Rheum 1996;26:459-67.
23. Kinebuchi S, Mizuno K, Moriyama H, et al. Two cases of interstitial pneumonia with anti-Jo-1 antibodies in the absence of myositis. Nihon Kokyuki Gakkai Zasshi 2003;41:739-45.
24. Sauty A, Rochat T, Schoch OD, et al. Pulmonary fibrosis with predominant CD8 lymphocytic alveolitis and anti-Jo-1 antibodies. Eur Respir J 1997;10:2907-12.
25. American Thoracic Society/European Respiratory Society. International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. Am J Respir Crit Care Med 2002;165:277- 304.
26. BAL Cooperative Group Steering Committee. Am Rev Respir Dis 1990;141:S199.
27. American Thoracic Society. Consensus. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. Am J Respir Crit Care Med 2000;161:646-64.
28. Hengstman GJ, van Engelen BG, van Venrooij WJ. Myositis-specific autoantibodies: changing insights in pathophysiology and clinical associations. Curr Opin Rheumatol 2004;16:692-9.
29. Marguerie C, Bunn CC, Beynon HLC, et al. Polymyositis, pulmonary fibrosis and autoantibodies to aninoacyl-tRNA synthase enzymes. Q J Med 1990;282:1019-38.
30. Kashiwabara K, Ota K. Rapidly progressive interstitial lung disease in a dermatomyositis patient with high levels of creatine phosphokinase, severe muscle symptoms and positive anti-Jo-1 antibody. Intern Med 2002;41:584-8.
31. Mathews MB, Bernstein RM. Myositis autoantibody inhibits histidyl-tRNA synthetase: a model for autoimmunity. Nature 1983;304:177-9.
32. Nishikai M, Reichlin M. Heterogeneity of precipitating antibodies in polymyositis and dermatomyositis. Characterization of the Jo-1 antibody system. Arthritis Rheum 1980;23:881-8.
33. Otero C, Illa I, Dalakas MC. Is there dermatomyositis without myositis? Neurology 1992;42:388.
34. Le Faou AL, Scemama O. Epidemiology of tobacco smoking. Rev Mal Respir 2005;22:8S27-32.
35. Hubbs A, Greskevitch M, Kuempel E, et al. Abrasive blasting agents: designing studies to evaluate relative risk. J Toxicol Environ Health A 2005;68:999-1016.
36. Love LA, Miller FW. Noninfectious environmental agents associated with myopathies. Curr Opin Rheum 1993;5:712-8.
37. Serratrice J, Granel B, Pache X, et al. A case of polymyositis with anti-histidyl-t-RNA synthetase (Jo-1) antibody syndrome following extensive vinyl chloride exposure. Clin Rheumatol 2001;20:379-82.
38. Brouwer R, Hengstman GJ, Vree Egberts W, et al. Autoantibody profiles in the sera of European patients with myositis. Ann Rheum Dis 2001;60:116-23.
39. Troyanov Y, Targoff IN, Tremblay JL, et al. Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients. Medicine (Baltimore) 2005;84:231-49.
40. Hill CL, Zhang Y, Sigurgeirsson B. Frequency of specific cancer types in dermatomyositis or polymyositis: a population-based study. Lancet 2001;357:96-100.
41. Ito M, Kaise S, Suzuki S, et al. Clinico-laboratory characteristics of patients with dermatomyositis accompanied by rapidly progressive interstitial lung disease. Clin Rheumatol 1999;18:462-7.
42. Clawson K, OddisC. Adult respiratory distress syndrome in polymyositis patients with the anti Jo-1 antibody. Arthritis Rheum 1995;38:1519-23.
43. Temmesfeld-Wollbruck B, Morr H, Suttorp N, et al. Three cases of a fulminant course of idiopathic pulmonary fibrosis (Hamman-Rich syndrome). Pneumologie 1993;47:573-8.
44. Takizawa H, Shiga J, Moroi Y, et al. Interstitial lung disease in dermatomyositis: clinicopathological study. J Rheumatol 1987;14:102-7.
45. Akira M, Hara H, Sakatani M. Interstitial lung disease in association with polymyositis-dermatomyositis: long-term follow-up CT evaluation in seven patients. Radiology 1999;210:333-8.
46. Veeraraghavan S, Latsi PI, Wells AU, et al. BAL findings in idiopathic nonspecific interstitial pneumonia and usual interstitial pneumonia. Eur Respir J 2003;22:239-44.
47. Raghu G, Mageto YN, Lockhart D, et al. The accuracy of the clinical diagnosis of new-onset idiopathic pulmonary fibrosis and other interstitial lung disease: a prospective study. Chest 1999;116:1168-74.
48. Johnson MA, Kwan S, Snell NJ, et al. Randomised controlled trial comparing prednisolone alone with cyclophosphamide and low dose prednisolone in combination in cryptogenic fibrosing alveolitis. Thorax 1989;44:280-8.
49. Tanaka F, Origuchi T, Migita K, et al. Successful combined therapy of cyclophosphamide and cyclosporine for acute exacerbated interstitial pneumonia associated with dermatomyositis. Intern Med 2000;39:428-30.
50. Yoshida T, Koga H, Saitoh F, et al. Pulse intravenous cyclophosphamide treatment for steroid-resistant interstitial pneumonitis associated with polymyositis. Intern Med 1999;38:733-8.
51. Dalakas MC. Therapeutic approach in patients with inflammatory myopathies. Semin Neurol 2003;23:199-206.
52. Schnabel A, Reuter M, Gross WL. Intravenous pulse cyclophosphamide in the treatment of interstitial lung disease due to collagen vascular diseases. Arthritis Rheum 1998;41:1215-20.
53. Dawson JK, Abernethy VE, Lynch MP. Effective treatment of anti Jo-1 antibody positive polymyositis with cyclosporin. Br J Rheumatol 1997;36:144-5.
54. Nawata Y, Kurasawa K, Takabayashi K, et al. Corticosteroid resistant interstitial pneumonitis in dermatomyositis/polymyositis: prediction and treatment with cyclosporine. J Rheumatol 1999;26:1527-33.